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 Polypharmacy describes, in simplistic terms, the use of mul-
tiple medications in an individual. It has become a normal 
aspect of modern medicine, driven by an ageing, multimorbid 
population, the increasing availability of preventative medica-
tions and an increasing use of single-disease guidelines and 
adherence to evidence-based practice. However, polypharmacy 
is also associated with a range of adverse outcomes, and is 
considered an important and increasing challenge for clinical 
practice. Here, we consider the deﬁ nitions of polypharmacy, 
the extent and nature of medication use in different settings, 
and the type of problems encountered as a consequence of 
polypharmacy. 
 Introduction 
 Polypharmacy is considered an important and growing 
challenge for modern clinical practice, attracting interest from 
clinicians, guideline developers and policymakers alike. Here, 
we consider the magnitude of the problem in the general adult 
population from an epidemiological perspective, drawing on 
evidence from a narrative review of the literature. 
 Deﬁnition of polypharmacy 
 The word polypharmacy is derived from the ancient Greek 
‘polús’ meaning ‘many’, and ‘pharmakeía’ meaning ‘the use of 
drugs’. This broad meaning from a purely linguistic perspective 
is reflected in the fact that there is no consensus on a clinical 
definition of polypharmacy. For example, should the term refer 
to only simultaneous opposed to consecutive medications, 
include short-term as well as long-term therapy, be restricted to 
prescription-only medications, or include non-pharmacological 
products? These points make it difficult to accurately quantify 
the extent of the issue or enable comparisons between health 
systems or care settings. 
 One of the most commonly employed definitions of 
polypharmacy in practice is the number of medications 
exceeding a simple numeric threshold (although how 
medications are counted is subject to the issues above). 
Although having the advantage of simplicity, polypharmacy is 
a continuum and dichotomising in this way is of limited value 
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in assessing drug-related problems. 1 Furthermore, increased 
medication use in current practice means that previously 
relevant cut-offs such as ‘five or more drugs’ may no longer be 
appropriate. 
 An even more important limitation to the use of simple 
thresholds is a failure to capture the appropriateness or 
otherwise of treatment. A King’s Fund report on the subject 
advocated classification of polypharmacy as either appropriate 
or problematic. 2 The former was defined as ‘prescribing for an 
individual for complex conditions or for multiple conditions 
in circumstances where medicines use has been optimised 
and the medicines are prescribed according to best evidence’, 
with the intent of improving quality of life and longevity while 
minimising harm. Problematic polypharmacy was defined as 
‘where multiple medications are prescribed inappropriately, or 
where the intended benefit of the medication is not realised’, 
potentially through non-evidence-based therapy, unfavourable 
risk-benefit balance, hazardous interactions, unacceptable 
treatment burden or poor adherence, or an undesirable 
prescribing cascade. 
 Key points 
 Polypharmacy is a common issue encountered in both 
primary and secondary care, and should be differentiated into 
appropriate or problematic 
 There is no accepted means of measuring either magnitude 
or appropriateness of polypharmacy. Nevertheless, a range 
of clinical indicators exist for the identification of potentially 
inappropriate prescribing, which are relevant (but not specific) 
to problematic polypharmacy 
 Increasing age, multimorbidity and widespread use of 
evidence-based clinical guidelines are strongly associated with 
increased polypharmacy 
 Polypharmacy is associated with a range of adverse clinical 
outcomes, but the use of multiple medications is not always 
harmful and the clinical context of treatment should be 
considered 
 KEYWORDS :  Multimorbidity ,  pharmacoepidemiology , 
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 However, this qualitative definition is not straightforward 
to implement in clinical informatics systems and not readily 
applicable to epidemiological studies. A 2014 systematic 
review identified 46 different tools for assessing inappropriate 
prescribing, the majority (36) focusing on the older 
population. 3 Tools were categorised as explicit, criterion-based 
tools (eg Beers’ criteria, 4 STOPP (Screening Tool of Older 
People’s potentially inappropriate Prescriptions)/START 
(Screening Tool to Alert doctors to Right Treatment) criteria 5 ), 
implicit, judgement-based tools (eg Medication Appropriateness 
Index 6 ), or a combination (Box  1 ). Explicit criteria are lists 
of potentially inappropriate prescribing specific to particular 
drugs, generally identified through expert consensus. These 
criteria have the advantage of being readily implemented into 
automated systems, but are restricted to finite numbers of 
drug- or disease-specific problems. In contrast, implicit criteria 
can be applied to any medication, but generally require human 
evaluation and are relatively subjective. None of these tools are 
specifically designed for measuring problematic polypharmacy 
although implicit tools are arguably better suited to this by 
capturing the entirety of the patient’s medication regimen; a 
handful of such indicators have been devised for optimising 
polypharmacy. 3 
 Extent of polypharmacy in the UK and beyond 
 In a study by Guthrie and colleagues, 7 the numbers of Scottish 
adults dispensed 5–9, 10–14, or 15 or more medications in 
primary care over a 3-month period in 2010 were 16.3%, 4.7% 
and 1.1%, respectively. These figures had increased from 9.7%, 
1.5% and 0.2%, respectively, in 1995. The most frequently 
prescribed medications are shown in Fig  1 . Just under a quarter 
of adults were dispensed medications from three or more 
chapters of the British National Formulary. 7 Importantly, 
these data do not distinguish appropriate from problematic 
polypharmacy, although rates of inappropriate prescribing 
have been reported; a UK study found that the prevalence 
of potentially inappropriate prescribing (a composite of 13 
indicators) in all patients at risk of exposure was around 5% 8 
and an Irish study using 30 STOPP criteria reported a prevalence 
of over a third in older patients. 9 Differences in the way data 
are captured and polypharmacy is defined makes international 
comparison challenging but the issue is nevertheless a global 
one. 11% of the Swedish primary care population 10 and 6% 
of a rural Chinese population were in receipt of five or more 
medications; 11 two-thirds of over-60s in a Brazilian primary 
care study received four or more medications. 12 
 Age and multimorbidity are important factors driving 
polypharmacy. The UK population is predicted to grow by 15% 
over the next 25 years, with 1 in 12 people being over the age of 
80 years by 2039, 13 and approximately a quarter of the UK adult 
population have two or more long-term health conditions. 14 
Fig  2 summarises evidence from another Scottish study 
showing polypharmacy to have a strong positive association 
with both number of clinical conditions and increasing age. 15 
Patients in receipt of higher numbers of medications are also 
more likely to be female, more socio-economically deprived and 
live in care homes. 7,15 There is considerable variation in types 
of conditions for which multiple medication use is observed, 
with the highest level of prescribing observed in cardiovascular 
disease, clinically unrelated problems and other conditions 
managed using complex medication regimens. 15 
 Clinical guidelines play an increasingly major role in 
clinicians’ therapeutic decision making around long-term 
conditions. However, most guidelines are designed with single 
diseases in mind, rather than the holistic care of patients. It is 
difficult to quantify the effect of guidelines on the growth of 
polypharmacy. In the UK, the National Institute for Health and 
Care Excellence has published over 170 clinical guidelines to 
date; this has increased from three new guidelines in 2004 to 21 
in 2015. There is evidence that such guidelines impact directly 
on clinicians’ prescribing behaviours 16 and a study examining 
the potential impact of guideline adherence in a hypothetical 
clinical situation found this would lead to considerable 
treatment burden. 17 
 Box 1.  Indicators of potentially inappropriate 
prescribing 
Selected examples of explicit indicators from the STOPP criteria 5 
> Beta-blocker in combination with verapamil or diltiazem
>  Aspirin with a past history of peptic ulcer disease without 
concomitant PPI
>  Initiation of tricyclic antidepressants as first-line 
antidepressant treatment
>  Direct thrombin inhibitors (eg dabigatran) if eGFR<30 mL/
min/1.73m 2 
>  Systemic corticosteroids instead of inhaled corticosteroids for 
maintenance therapy in moderate-severe COPD
>  NSAID with established hypertension or heart failure
>  Selective alpha-1 selective alpha blockers in those with 
symptomatic orthostatic hypotension
>  Oestrogens with a history of breast cancer or venous 
thromboembolism
>  Use of regular (as distinct from PRN) opioids without 
concomitant laxative
Full list of implicit indicators from the Medication Appropriateness 
Index 6 
>  Is there an indication for the drug?
>  Is the medication effective for the condition?
>  Is the dosage correct?
>  Are the directions correct?
>  Are the directions practical?
>  Are there clinically significant drug-drug interactions?
>  Are there clinically significant drug-disease/condition 
interactions?
>  Is there unnecessary duplication with other drug(s)?
>  Is the duration of therapy acceptable?
>  Is this drug the least expensive alternative compared to others 
of equal utility?
 COPD = chronic obstructive pulmonary disease; eGFR = estimated glomerular 
filtration rate; NSAID = Nonsteroidal anti-inflammatory drug; PPI = proton 
pump inhibitor; PRN = pro re nata (when required); STOPP = Screening Tool of 
Older People’s potentially inappropriate Prescriptions 
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 Admission to hospital is an important driving factor behind 
polypharmacy, although UK data is lacking. A cross-European 
study by Gallagher and colleagues reported the median number 
of medications in older inpatients to be 6 (interquartile range 
4–9). 18 A number of studies have described the impact of 
hospitalisation upon prescribing rates; an Australian study 
reported an increase following acute admission to an elderly 
care unit of 6.6 to 7.7 long-term medications, most marked in 
younger patients (65–75 years). 19 Importantly, considerable 
changes are often made to medication regimens in the weeks 
and months after discharge, with one study finding this affected 
86% of patients. 20 
 Consequences of polypharmacy 
 Medication safety issues are common and there is strong 
evidence that these are associated with polypharmacy. 
Commissioned by the General Medical Council, the 
PRACtICe (PRevalence And Causes of prescrIbing errors in 
general practiCe) study of UK general practice prescribing 
errors found the odds of a medication error increased by 
16% for each additional medication prescribed, although 
medication appropriateness was not considered. 21 Prescribing 
or monitoring errors were observed in one in eight patients, 
affecting 5% of all prescription items. The total number 
 Fig 1.  Percentages of adults pre-
scribed medications in Scottish 
primary care in 2010 according 
to chapter in the British National 
Formulary. O&G = obstetrics and 
gynaecology. Data from Guthrie 
et al. 7 
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 Fig 2.  Percentage of Scottish adults 
on given number of medications by 
age (A) and number of conditions (B). 
Adapted with permission from Payne 
et al. 15 
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interventions. A recent Cochrane review identified 12 
interventions designed to improve appropriate use of 
polypharmacy in older patients. 29 The majority of these were 
multifaceted complex interventions delivered by pharmacists, 
and provided at various points in the care pathway. 
Intervention components included medication review, patient 
education, health professional training, medication adherence 
aids and multidisciplinary case conferences. Studies were of 
limited quality and focused on reducing medication count 
as opposed to prescribing appropriateness. Reductions in 
inappropriate prescribing were observed although there was 
a lack of evidence of benefit in terms of clinical outcomes. 
National guidance has been issued on the management of 
polypharmacy in both Scotland 30 and Wales 31 , and key aspects 
of these are summarised in Box  2 . 
 Conclusion 
 Polypharmacy is a growing and global issue, affecting primary 
and secondary care. It is predominantly driven by an ageing, 
multimorbid population coupled with the increasing use of 
evidence-based clinical guidelines. Clinicians need to be aware 
of the range of problems it can lead to and ensure the benefits of 
using multiple medications are balanced appropriately against 
the potential harms. ■
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